{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:35Z","timestamp":1790701535929,"version":"4.1.0"},"reference-count":34,"publisher":"American Society for Microbiology","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>WCK 6777 is a novel once-daily \u03b2-lactam enhancer combination comprising ertapenem (ERT) and zidebactam (ZID), designed to expand ERT activity against multidrug-resistant gram-negative Enterobacterales, including serine- and metallo-\u03b2-lactamase producers. This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluated the safety, tolerability, and pharmacokinetics (PK) of WCK 6777 and its individual components following once-daily intravenous administration for 7 days in healthy adults. In total, 54 participants were enrolled, of whom 52 received ERT alone (2 or 3 g), ZID alone (2 or 3 g), WCK 6777 (ERT + ZID at 1 + 1, 2 + 2, or 3 + 3 g), or placebo. Safety assessments included adverse events, clinical laboratory testing, vital signs, and electrocardiography. Plasma and urine PK of total and unbound ERT and ZID were characterized using noncompartmental methods. WCK 6777 was safe and well tolerated at all dose levels, with no deaths, serious adverse events, or treatment discontinuations. Adverse events were predominantly mild or moderate and were most commonly infusion-site reactions. Both ERT and ZID exhibited predictable, time-independent PK. Ertapenem exhibited a biphasic disposition with a terminal half-life supportive of once-daily dosing, whereas ZID displayed linear PK across the evaluated dose range. Plasma exposure, clearance, protein binding, and renal excretion were comparable between monotherapy and combination regimens, indicating no clinically meaningful PK interaction. Both drugs were eliminated predominantly unchanged in urine. In summary, WCK 6777 demonstrated a favorable safety profile and predictable PK following once-daily administration, supporting further clinical development, including evaluation in Phase II\/III efficacy studies and potential application in outpatient parenteral antimicrobial therapy.<\/jats:p>\n                    <jats:sec>\n                      <jats:title>CLINICAL TRIALS<\/jats:title>\n                      <jats:p>\n                        This study is registered with ClinicalTrials.gov as\n                        <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT05645757\" document-id-type=\"clinical-trial-number\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05645757\">NCT05645757<\/jats:related-object>\n                        .\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00390-26","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:27:50Z","timestamp":1790699270000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["A Phase I, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of intravenous ertapenem and zidebactam in combination (WCK 6777) in healthy adult subjects"],"prefix":"10.1128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":true,"given":"T. P.","family":"Lodise","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/014hfaw95","id-type":"ROR","asserted-by":"publisher"}],"name":"Albany College of Pharmacy and Health Sciences","place":["Albany, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Chavan","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre","place":["Chhatrapati Sambhaji Nagar, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre","place":["Chhatrapati Sambhaji Nagar, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yeole","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre","place":["Chhatrapati Sambhaji Nagar, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bhagwat","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre","place":["Chhatrapati Sambhaji Nagar, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Patel","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre","place":["Chhatrapati Sambhaji Nagar, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. A.","family":"Saviolakis","sequence":"additional","affiliation":[{"name":"DynPort Vaccine Company","place":["Frederick, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kankam","sequence":"additional","affiliation":[{"name":"Altasciences Clinical Kansas, Inc.","place":["Overland Park, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Gu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/045p44t13","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ghazaryan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/045p44t13","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jaunarajs","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC","place":["Rockville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Fairfax","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC","place":["Rockville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Howell","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC","place":["Rockville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3299-894X","authenticated-orcid":true,"given":"R. A.","family":"Bonomo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041sxnd36","id-type":"ROR","asserted-by":"publisher"}],"name":"Infectious Diseases Section, Medical and Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Geriatric Research Education and Clinical Center (GRECC), VA Northeast Ohio Healthcare System","place":["Cleveland, USA"]},{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Case Western Reserve University","place":["Cleveland, USA"]},{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Molecular Biology and Microbiology, Case Western Reserve University","place":["Cleveland, USA"]},{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Biochemistry, Case Western Reserve University","place":["Cleveland, USA"]},{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacology, Case Western Reserve University","place":["Cleveland, USA"]},{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Proteomics and Bioinformatics, Case Western Reserve University","place":["Cleveland, USA"]},{"name":"Case VA CARES, Louis Stokes Cleveland Department of Veterans Affairs Medical Center","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"e_1_3_6_2_2","unstructured":"WHO. 2019. Ten threats to global health in 2019. Available from: https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in"},{"key":"e_1_3_6_3_2","unstructured":"CDC. 2019. Antibiotic resistance threats in the united States 2019. Atlanta GA: U.S Department of Health and Human Services CDC. www.cdc.gov\/DrugResistance\/Biggest-Threats.html."},{"key":"e_1_3_6_4_2","unstructured":"WHO. 2017. List of bacteria for which new antibiotics are urgently needed. Available from: https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria- for-which-new-antibiotics-are-urgently-needed"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-19"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00472-17"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1222343"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01264.x"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.03.012"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.09.001"},{"key":"e_1_3_6_11_2","unstructured":"Anonymous. 2026. IDSA facts on antibacterial resistance. Available from: https:\/\/www.idsociety.org\/policy--advocacy\/antimicrobial-resistance\/strengthening-u.s.-efforts\/"},{"key":"e_1_3_6_12_2","unstructured":"Anonymous. 2022. RECARBRIO (imipenem cilastatin and relebactam) for injection for intravenous use. Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/r\/recarbrio\/recarbrio_pi.pdf. Retrieved 1 Feb 2022."},{"key":"e_1_3_6_13_2","unstructured":"Anonymous. 2015. AVYCAZ (ceftazidime and avibactam) for Injection for intravenous use. Package insert. https:\/\/www.allergan.com\/assets\/pdf\/avycaz_pi."},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz830"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025247"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy745"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2014.23.sup14.s30"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks193"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac280"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac110"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg375"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx438"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00091"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa036"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01648-19"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-19"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02146-18"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1784"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae111"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh209"},{"key":"e_1_3_6_32_2","unstructured":"Anonymous. 2012. INVANZ prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021337s038lbl.pdf"},{"key":"e_1_3_6_33_2","unstructured":"Anonymous. 2016. PRIMAXIN (imipenem and cilastatin) for Injection for intravenous use. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050587s074lbl.pdf"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.521-524.2004"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3506-3511.2002"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00390-26","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00390-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:27:53Z","timestamp":1790699273000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00390-26"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":34,"alternative-id":["10.1128\/aac.00390-26"],"URL":"https:\/\/doi.org\/10.1128\/aac.00390-26","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"2026-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00390-26"}}